Zosano Pharma Corp.’s (ZSAN) New Drug Application for Qtrypta awaits the FDA decision on October 20, 2020.Qtrypta, proposed for the acute treatment of migraine, is a proprietary formulation of Zolmitriptan, administered via the company's intracutaneous microneedle-array drug-delivery system. Zolmitriptan as a tablet and an orally disintegrating tablet (tablet that dissolves quickly in the mouth) is already used to treat acute migraine headaches in adults. According to the company, Qtrypta has the potential to offer patients rapid, sustained pain relief with no recurrence. Qtrypta represents the first pharmaceutical microneedle patch to be submitted to the FDA for review.If approved, H.C. Wainwright analyst Raghuram Selvaraju expects Qtrypta to generate $30 million in sales during 2021 and peak sales of about $300 million in 2026.ZSAN closed Friday’s (Sep.25, 2020) trading at $1.70, up 8.9%.